Beamr video compression achieves up to 50% improvement for AVs
Segal Lloyd Mitchell, President and CEO of Repare Therapeutics Inc . (NASDAQ:RPTX), recently sold 21,179 common shares of the company. The shares were sold at a price of $1.14 each, totaling $24,144, near the stock’s 52-week low of $1.06. Following this transaction, Mitchell’s direct ownership stands at 124,394 shares. According to InvestingPro data, RPTX shares have declined nearly 79% over the past year, though analysis suggests the stock may be undervalued at current levels.
The transaction, reported on March 12, 2025, was conducted to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units. It was not a discretionary sale by Mitchell. Additionally, Mitchell holds an indirect ownership of 107,558 shares registered under Arvala Inc., a company for which he is the sole stockholder. InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 6.77 and holds more cash than debt, though it’s currently burning through cash reserves. Subscribers can access 8 additional ProTips and detailed financial metrics on the platform.
In other recent news, Repare Therapeutics reported a diluted net loss of $2.00 per share for 2024, aligning with forecasts from H.C. Wainwright, which also noted R&D and SG&A expenses slightly below estimates. The company anticipates key clinical trial results by late 2025, focusing on three Phase 1 trials, including the POLAR and LIONS trials, with significant data expected. Despite a workforce reduction of about 75%, Repare aims to extend its financial runway into late 2027, supported by $152.8 million in cash and equivalents. Analyst firms have varied opinions on Repare’s stock, with H.C. Wainwright lowering the price target to $5 but maintaining a Buy rating, while Stifel reduced its target to $3, also keeping a Buy rating due to optimism about early-stage assets like RP-3467 and RP-1664. Conversely, Bloom Burton downgraded the stock to Hold, citing the absence of human data for key drugs and removing the price target until more information is available. The strategic pivot away from lunresertib and camonsertib has influenced these ratings, highlighting the importance of forthcoming clinical data. As Repare shifts focus, investors await further developments that could impact the company’s valuation and analyst recommendations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.